Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis

Laboratory Investigation

Volumn 79, Issue 9, 1999, Pages 1059-1067

  Yamada, Yoshihisa ^a   Karasaki, Hidenori ^a   Matsushima, Kouji ^b   Lee, Gang Hong ^a   Ogawa, Katsuhiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; CYTOCHROME P450; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CLONING, MOLECULAR; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED STRAINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEINS; RECEPTORS, INTERLEUKIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALOGLYCOPROTEINS;

EID: 0032852891     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Arend WP, Malyak M, Guthridge CJ, and Gabay C (1998). Interleukin-1 receptor antagonist: Role in biology. Annu Rev Immunol 16:27-55.
2. Becker FF and Stout DL (1984). A constitutive deficiency in the monooxygenase system of spontaneous mouse liver tumors. Carcinogenesis 5:785-788.
3. Begun NA, Mori M, Matsumata T, Takenaka K, Sugimachi K, and Barnard GF (1995). Differential display and integrin alpha 6 messenger RNA overexpression in hepatocellular carcinoma. Hepatology 22:1447-1455.
4. Boulton R, Woodman A, Calnan D, Selden C, Tam F, and Hodgson H (1997). Nonparenchymal cells from regenerating rat liver generate interleukin-1α and -1β: A mechanism of negative regulation of hepatocyte proliferation. Hepatology 26:49-58.
5. Brown T (1993). Preparation and analysis of RNA. In: Ausbel FM, Brent R, Kingston RE, Moore DM, Seidman JG, Smith JA, and Struhl K, editors. Current protocols in molecular biology. New York: Greene Publishing Associates, Inc., and John Wiley & Sons, Inc., 4.9.1-4.9.14.
6. Buchmann A, Schwarz M, Schmitt R, Wolf CR, Oesch F, and Kunz W (1987). Development of cytochrome P-450-altered preneoplastic and neoplastic lesions during nitrosamine-induced hepatocarcinogenesis in the rat. Cancer Res 47: 2911-2918.
7. Burger RA, Grosen EA, Ioli GR, Van Eden ME, Brightbill HD, Gatanaga M, Disaia PJ, Granger GA, and Gatanaga T (1994). Host-tumor interaction in ovarian cancer. Gynecol Oncol 55:294-303.
8. Dietrich DR (1993). Toxicological and pathological applications of proliferating cell nuclear antigen (PCNA), a novel endogenous marker for cell proliferation. Crit Rev Toxicol 23:77-109.
9. Dinarello CA (1996). Biologic basis for interleukin-1 in disease. Blood 87:2095-2147.
10. Dragani TA, Manenti G, Gariboldi M, Gregorio LD, and Pierotti MA (1995). Genetics of liver tumor susceptibility in mice. Toxicol Lett 82/83:613-619.
11. Dragani TA, Manenti G, Sacchi MRM, Colombo BM, and Della Porta G (1989). Major urinary protein as a negative tumor marker in mouse hepatocarcinogenesis. Mol Carcinog 2:355-360.
12. Drinkwater NR and Lee G-H (1995). Genetic susceptibility to liver cancer. In: Jirtle RL, editor. Liver regeneration and carcinogenesis: Molecular and cellular mechanisms. San Diego: Academic Press, 301-321.
13. Farber E (1984). The biochemistry of preneoplastic liver: A common metabolic pattern in hepatocyte nodules. Can J Biochem Cell Biol 62:486-494.
14. Flower DR (1996). The lipocalin protein family: Structure and function. Biochem J 318:1-14.
15. Frith CH and Ward JM (1979). A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol 3:329-351.
16. Fujioka N, Mukaida N, Harada A, Akiyama M, Kasahara T, Kuno K, Ooi A, Mai M, and Matsushima K (1995). Preparation of specific antibodies against murine IL-1ra and the establishment of IL-1ra as an endogenous regulator of bacteriainduced fulminant hepatitis in mice. J Leukoc Biol 58:90-98.
17. Gabay C, Porter B, Fantuzzi G, and Arend WP (1997a). Mouse IL-1 receptor antagonist isoforms: Complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. J Immunol 159:5905-5913.
18. Gabay C, Smith MF Jr, Eidlen D, and Arend WP (1997b). Interleukin 1 receptor antagonist (IL-1IRa) is an acute-phase protein. J Clin Invest 99:2930-2940.
19. Giri RK and Das BR (1996). Differential expression of c-jun and c-myc in N-nitroso diethylamine-induced hepatic oncogenesis in AKR mice. Cancer Lett 109:121-127.
20. Haskill S, Martin G, Van Le L, Morris J, Peace A, Bigler CF, Jaffe GJ, Hammerberg C, Sporn SA, Fong S, Arend WP, and Ralph P (1991). cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 88:3681-3685.
21. Hsu H-C, Cheng W, and Lai P-L (1997). Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: Biological significance and temporospatial distribution. Cancer Res 57:5179-5184.
22. Kilian PL, Kaffka KL, Biondi DA, Lipman JM, Benjamin WR, Feldman D, and Campen CA (1991). Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH: OVCAR-3). Cancer Res 51:1823-1828.
23. Lachman LB, Brown DC, and Dinarello CA (1987). Growth-promoting effect of recombinant interleukin 1 and tumor necrosis factor for a human astrocytoma cell line. J Immunol 138:2913-2916.
24. Liang P and Pardee AB (1992). Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 257:967-971.
25. Maier JAM, Voulalas P, Roeder D, and Maciag T (1990). Extension of the life-span of human endothelial cells by an interleukin-1α antisense oligomer. Science 249:1570-1574.
26. Maronpot RR, Fox T, Malarkey DE, and Goldsworthy TL (1995). Mutations in the ras proto-oncogene: Clues to etiology and molecular pathogenesis of mouse liver tumors. Toxicology 101:125-156.
27. Moore MA and Kitagawa T (1986). Hepatocarcinogenesis in the rat: The effects of promoters and carcinogens in vivo and in vitro. Int Rev Cytol 101:125-173.
28. Nakamura T, Araki R, and Ichihara A (1988). Interleukin-1β is a potent growth inhibitor of adult rat hepatocytes in primary culture. Exp Cell Res 179:488-497.
29. Nishida N, Fukuda Y, and Ishizaki K (1994). Molecular aspects of hepatocarcinogenesis and their clinical implications. Int J Oncol 4:615-622.
30. Oelmann E, Kraemer A, Serve H, Reufi B, Oberberg D, Patt S, Herbst H, Stein H, Thiel E, and Berdel WE (1997). Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 71:1066-1076.
31. Pitot HC (1990). Altered hepatic foci: Their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 30:465-500.
32. Rokita H, Kosz-Vnenchak M, Stalinska K, and Stachura J (1997). Interleukin 1 receptor antagonist localization exclusively in non-parenchymal cells of the mouse liver. Cytokine 9:249-253.
33. 1 mice. Mol Carcinog 19:31-38.
34. Scuric Z, Stain SC, Anderson WF, and Hwang J-J (1998). New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 27:943-950.
35. Smith DR, Kunkel SL, Standiford TJ, Chensue SW, Rolfe MW, Orringer MB, Whyte RI, Burdick MD, Danforth JM, Gilbert AR, and Strieter RM (1993). The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. Am J Pathol 143:794-803.
36. Steinkasserer A, Estaller C, Weiss EH, and Sim RB (1992). Human interleukin-1 receptor antagonist is expressed in liver. FEBS Lett 310:60-62.
37. Van Le L, Haskill S, Jaffe GJ, and Fowler WC (1991). Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer. Gynecol Oncol 42:161-164.
38. Vesselinovitch SD and Mihailovich N (1983). Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res 43:4253-4259.
39. Vogelstein B and Kinzler KW (1993). The multistep nature of cancer. Trends Genet 9:138-141.
40. Wang Z, Wang M, and Carr BI (1998). The inhibitory effect of interleukin 1β on rat hepatocyte DNA synthesis is mediated by nitric oxide. Hepatology 28:430-435.
41. Ward JM, Shibata M, and Devor DE (1996). Emerging issues in mouse liver carcinogenesis. Toxicol Pathol 24:129-137.
42. Zahedi KA, Uhlar CM, Rits M, Prada AE, and Whitehead AS (1994). The mouse interleukin 1 receptor antagonist protein: Gene structure and regulation in vitro. Cytokine 6:1-9.